

Global Burden of Disease

Mental Disorders and Illicit Drug Use Expert Group



**Summary of data collected and decision rules
used in making regional and global estimates:**

Anxiety Disorders

**Amanda Baxter, Adele Somerville, An Pham, Allison Ventura,
Roman Scheurer, Bianca Calabria, Jen McLaren, Anna
Roberts, Louisa Degenhardt and Harvey Whiteford *for the
Mental Disorders and Illicit Drug Use Expert Group***

**Summary of data collected and decision rules used in
making regional and global estimates:**

Anxiety Disorders

**Amanda Baxter, Adele Somerville, An Pham, Allison Ventura, Roman
Scheurer, Bianca Calabria, Jen McLaren, Anna Roberts, Louisa
Degenhardt and Harvey Whiteford for
*the Mental Disorders and Illicit Drug Use Expert Group***

Working Paper

© Policy and Economics Group, Queensland Centre for Mental Health Research, University of
Queensland, Brisbane, Australia, 2008

**This work is copyright. You may download, display, print and reproduce this material in unaltered form only
(retaining this notice) for your personal, non-commercial use or use within your organisation.**

**All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed
to [the Research Manager, QCMHR, Brisbane, QLD 4074, Australia.](#)**

Acknowledgments:

The Mental Disorders and Illicit Drug Use Expert Group comprise: Prof Harvey Whiteford (Co-Chair), Prof Louisa Degenhardt (Co-Chair), Prof Oye Gureje, Prof Wayne Hall, Dr Cille Kennedy, Prof Ron Kessler, Prof John McGrath, Dr Maria Medina-Mora, Dr Guilherme Polanczyk, Prof Martin Prince, and Dr Shekhar Saxena.

The authors wish to express their gratitude to staff of The Park, Centre for Mental Health Library and the University of Queensland Library, Ms Amanda Brown, Mrs Keryl Michener and all colleagues who assisted in the data search and extraction.

Table of Contents

Glossary	5
Preliminary data coverage identified for: Anxiety Disorders	6
1.0 Data summary and decision rules overview	7
1.1 Data sources	8
2.0 Principles for inclusion of data sources and reporting of data.....	10
2.1 Inclusion of Data Sources (including Peer-review papers).....	10
2.2 Data Extraction and Reporting	11
3.0 Data sources for anxiety disorders.....	14
3.1 Prevalence data	14
Table 1. Summary of data sources available by country for the prevalence of anxiety disorders.....	14
3.2 Remission data.....	21
3.3 Mortality data.....	21
4.0 Principles for data manipulation and imputation	22
4.1 Prevalence estimates - data manipulation and imputation.....	22
4.2 First steps of data manipulation and imputation.....	24
Table 2. Ratios of lifetime, past year and past month prevalence of anxiety disorders.....	24
4.3 Remission estimates - data manipulation and imputation	26
4.4 Mortality estimates - data manipulation and imputation	26
Reference List.....	27
Appendix	31

Glossary

ARR	Annualised remission rate
CIDI	Composite International Diagnostic Interview
DALY	Disability-adjusted life year
DSM	Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association)
GAD	Generalised anxiety disorder
GBD	Global Burden of Disease Project
ICD	International Classification of Diseases (World Health Organisation)
LP	Lifetime prevalence
OCD	Obsessive compulsive disorder
PTSD	Post-traumatic stress disorder
PMP	Past month prevalence
PYP	Past year prevalence
SDS	Sheehan Disability Scale
WHO	World Health Organisation
WMHS	World Mental Health Survey
YLD	Years of life lived with disability
YLL	Years of life lost

1.0 Data summary and decision rules overview

The new Global Burden of Disease study commenced in 2007 and is the first major effort since the original 1996 GBD study to produce systematic and comprehensive estimates of the burden of diseases and injuries. It will also update the comparative estimates of the burden of risk factors. While the original 1996 GBD study produced 1990 estimates for 107 diseases and injuries and ten risk factors for eight world regions, the new study will produce 1990 and 2005 estimates for 150 diseases and injuries and more than 40 risk factors for 21 regions of the world.

Important changes will be made to the scope and nature of the estimates for mental disorders and illicit drug use. More disorders are being considered because of significant advances in epidemiological research. The original study contained estimates for unipolar depression, bipolar disorder, panic disorder, obsessive compulsive disorder, post traumatic stress disorder and illicit drug use. The new estimates will include the mental disorders covered in the original study plus eating disorders (both anorexia and bulimia), dysthymia (as well as major depression), generalised anxiety disorder, agoraphobia, social phobia, specific phobia, separation anxiety disorder, pervasive developmental disorders (autism and Asperger's disorder), attention deficit hyperactivity disorder and conduct disorders.

In the 2005 update, **anxiety disorders** is defined as any ICD or DSM diagnosis of:

- panic disorder,
- obsessive compulsive disorder (OCD),
- post traumatic stress disorder (PTSD),
- generalised anxiety disorder (GAD),
- agoraphobia,
- social phobia,
- specific phobia, and
- separation anxiety disorder.

Anxiety disorders comprise three health states: mild, moderate and severe. These will be summed to give overall burden of disease for anxiety disorders.

1.1 Data sources

A systematic review was undertaken to identify sources of data containing epidemiologic parameters for anxiety disorders. Papers identified in the search were sought and data containing these parameters were extracted, recorded and standardised.

Standardised approaches to literature searches, data collection, data extraction, consistency and error checking, and expert consultation and review were taken across mental disorders. These methodologies are documented and detailed on the expert group's website: www.gbd.unsw.edu.au, but briefly can be summarised as follows:

The stages of the systematic review:

1. Search of peer-reviewed literature. The search strategy is consistent with the methodology recommended by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group[1] Three electronic databases were included in the search (Medline, PsychInfo and Embase) with searches limited to human subjects and publication dates of 1980 to 2007. Search strings are available for review at

<http://www.gbd.unsw.edu.au/gbdweb.nsf/page/Methodology>.

2. Identifying articles from peer-review literature that met inclusion criteria. An extensive list of articles was detected by the search string. Each of the several thousand articles was briefly reviewed for inclusion criteria:

- Must include the specific disorder under review
- Must present primary data
- Must be an epidemiologic study (pharmacological treatment samples and case studies excluded)
- Presented data for the period 1980 onward
- When general population data at a national level were available sub-national data was excluded.
- Samples must be representative of the general population

3. Obtaining full-text copies of articles. The references of articles identified from the systematic review were compiled in Endnote. PDFs were sourced from on-line open access journals and through The Park, Centre for Mental Health, Library and the University of Queensland Library.

4. Data extraction. A three level Access database was designed to accommodate the data from the mental disorders systematic search. A random sample of articles was double-checked for accuracy and consistency of data extraction and entry. In-built quality assurance was a feature of the Access database through the use of drop-down boxes and coding protocols.

A Quality Index Score was developed based on a range of variables extracted from each identified source of data so that representativeness of studies can be quantified and used for comparison. The Quality Index Score is available for review at

[http://www.gbd.unsw.edu.au/gbdweb.nsf/resources/MD_Pt2_Appendicies/\\$file/GBD2005+Mental+Disorders+Quality+Index.pdf](http://www.gbd.unsw.edu.au/gbdweb.nsf/resources/MD_Pt2_Appendicies/$file/GBD2005+Mental+Disorders+Quality+Index.pdf).

In this document we present an initial summary of the prevalence data identified for anxiety disorders.

We present the decision rules relating to :

- inclusion criteria for data sources,
- methodology of data extraction, and
- reporting of study characteristics and epidemiologic parameters.

Also presented here are some preliminary decision rules for:

- manipulating data,
- imputing missing data,
- pooling data within countries,
- pooling data for some parameters (for example remission and mortality), and
- our approach to production of regional prevalence estimates for mental disorders as a whole.

Further work is currently underway to identify peer-reviewed and grey literature sources that may assist with missing age-, sex- and country-specific estimates. The process of applying the rules outlined below has begun, with the first steps presented in this document.

2.0 Principles for inclusion of data sources and reporting of data.

Presented here are general rules for the inclusion of articles and data identified through the peer-review literature and through expert review. We also present the general protocol and rules for reporting of data.

2.1 *Inclusion of Data Sources (including Peer-review papers)*

Peer-review literature versus grey literature

A preliminary search for epidemiologic data for mental disorders identified a range of sources, including grey literature (government reports, unpublished findings, dissertations), peer-review publications and non-government organisation (NGO) data collection. Due to the wealth of data available (including data from the World Mental Health Survey) and the available time frame, the decision was taken to focus the first stage of the data search on peer-reviewed literature. Grey literature sources will be reviewed in the second stage of the project, as data sources to address the gaps in the preliminary dataset.

Justification: A large body of data is available through the peer-review literature, of sufficient quality to meet the expert group's criteria, to provide a preliminary dataset for the first round of estimates. It is anticipated that the circulation of these preliminary findings to experts in the field will yield a range of very useful suggestions for other data sources, including grey literature, to address the gaps in the data. In this way it is anticipated that maximum coverage will be achieved.

Representativeness

Where a large body of data is available for a country (e.g. for the US, Western Europe, Great Britain, New Zealand and Australia), only the nationally representative studies will be included.

Justification: Excluding studies that have small samples that are likely NOT representative of the national population will be a more time-efficient process. Studies with unrepresentative samples are unlikely to be used for this GBD Project.

Diagnostic Criteria

A broad rule was adopted for all mental disorders that initial data collection for prevalence, incidence and remission would be limited to data sources reporting estimates based on DSM or ICD diagnostic criteria only. Papers that report use of a survey that could not demonstrate validity against either DSM or ICD criteria were excluded. If the validity of a survey is uncertain, the opinion of an expert in the field will be sought.

Justification: Inclusion of estimates based on alternative definitions may skew the final estimates for some countries, as narrower or broader definitions would result in lower or higher estimates.

Definition of Remission

For the Global Burden of Disease project, remission from a mental disorder is defined as no longer fulfilling the diagnostic criteria for this disorder. Partial remission is therefore considered as being no longer a “case”. Follow-up period for the sample must be a minimum of two years.

Remission estimates were obtained from observational studies. Studies that reported samples from randomised controlled trials or treatment other than “as usual” will be excluded as not being representative of the average case. Remission among cases of mental disorders *in treatment* (that is, treatment “as usual”) will not be considered separately from out-of-treatment cases as so little data is available from community (non-treated) samples.

If several papers have been published for the same study (i.e same cohort) at different time points, only the paper reporting the longest follow-up period will be included in the dataset.

2.2 Data Extraction and Reporting

Prevalence rate

If prevalence type was unspecified, the diagnostic tool was sought in order to determine whether prevalence was point, past month, 12-month, lifetime or another period. If the diagnostic tool was unable to be accessed or unclear, prevalence was taken as point. An exception to this rule was for samples ascertained through case registries. As these were diagnosed with the disorder AT SOME PERIOD in their lives, but possibly some time ago, prevalence was taken as lifetime. As this was most frequently the case for disorders with zero remission in studies that used birth cohorts (e.g. autism), it is assumed that this will not make a significant difference to the rate.

Cohort

Cohort size was defined in different ways according to the methods used in the studies. Typically, cohort size was defined as the sample size, specifically the number of individuals for whom useable data was collected.

However, if the sample was derived from a case register or from medical records for a geographically defined area, and:

- the degree of coverage is difficult to ascertain due to inadequate reporting, or
- coverage appears to be poor (e.g. those who seek treatment in countries where a state-funded health system is not cheaply and easily accessible), or
- coverage is reliant on an individual actively seeking treatment for a disorder which is known to have a low level of treated prevalence (e.g. depression)

then the cohort size was recorded as the number of cases identified.

Alternatively, where health checks are legislated for infants and children at regular intervals (e.g. Norway and Japan) and coverage is close to 100% (95% or higher), cohort is taken as the number of children in that age group who fall within the defined area, as we can reasonably expect that data has been obtained for that number of people.

Time period (Epoch)

- Epoch not reported

Where epoch (the year to which the estimate refers) is NOT reported within a paper, a note will be made of the fact and epoch recorded as the year two years prior to publication.

Justification: The GBD Project requires the year of the estimate in order to establish a time trend for calculation of burden. However the research team found that it is relatively common for authors to not report details such as epoch, response rate, etc. Rather than leave a gap in the data where epoch is not reported, an overall decision was taken to estimate the epoch as two years prior to publication, on the basis that it will generally take at least two years to clean data, carry out analysis and publish results.

- Longitudinal studies

Where data collection is carried out over a period of time, the midpoint of the data collection period was taken as epoch start and midpoint of final follow-up period as epoch end. For example, if baseline data collection is 1980–1982 and final follow-up period is 2000–2004, epoch start is recorded as 1981 and epoch end as 2002. Greater detail of different time periods is recorded as text in the comments field.

- Studies that give estimates for different time periods

Where a longitudinal study gives year-specific estimates, the years that those estimates relate to are recorded as epoch start and epoch end. Again, greater detail is recorded as text in the comments field of the database. For example, if a longitudinal study reports 12-month prevalence for two samples, one ascertained 1980–1981 and the other 1990–1991, epoch is recorded as 1980–1981 for the prevalence rate specific to that particular time period and 1990–1991 for the relevant prevalence estimate.

Age Range

Where an age range is not reported in the paper, 'dummy' variables of 0 (minimum) and 99 (maximum) are inserted. If the sample is reported as 'adult' the age range was recorded as 18-99.

Remission and Mortality - Secondary Data Sources

In all cases, the primary source of data was used for all surveys for data extraction purposes. However, due to time restrictions, when a study reported data from previous years this data was included with a note that it did not come from the primary data source. Similarly, where a good quality systematic review or meta-analysis was identified, the data reported was included and clearly identified as coming from a secondary data source.

Prevalence by severity level

Two of the mental disorders covered in the GBD Project, major depressive disorder and anxiety disorders, comprise health states that will be categorised into three levels of severity (mild, moderate, severe). Prevalence for these health states will be calculated through applying population proportions derived from severity-specific prevalence estimates obtained through the World Mental Health Survey (WMHS) data using the WMHS CIDI Severity Measure[2, 3].

Justification: Issues identified in sourcing prevalence of mental disorders by severity level include the use of non-consistent definitions and differing measurement instruments across studies. The WMHS CIDI Severity Measure was administered across a range of mental disorders and across 23 cohorts in 22 countries as part of the World Mental Health Survey. Hence it is anticipated that proportions of mild, moderate, and severe cases can be derived for 22 developed and developing countries in 13 of the GBD regions. As the WMHS CIDI Severity Measure was applied consistently across these samples it can be used for imputing prevalence estimates by severity level for other countries and regions.

3.0 Data sources for anxiety disorders

3.1 Prevalence data

Table 1 presents the available data identified from an extensive search of the peer review literature (see www.gbd.unsw.edu.au for methodology). All data sources can be obtained from the reference list at the end of this report. The last two columns indicate whether ANY sex- and age-specific estimates were reported for that country (Y=Yes, N=No).

Table 1. Summary of data sources available by country for the prevalence of anxiety disorders.

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Asia Pacific, High Income					
Brunei	-	-	-		
Japan	[4]	[4]	-	Y	Y
Republic of Korea (South Korea)	-	[5]	[6, 7]	Y	Y
Singapore	-	-	-		
Asia, Central					
Armenia	-	-	-		
Azerbaijan	-	-	-		
Georgia	-	-	-		
Kazakhstan	-	-	-		
Kyrgyzstan	-	-	-		
Mongolia	-	-	-		
Tajikistan	-	-	-		
Turkmenistan	-	-	-		
Uzbekistan	-	-	-		
Asia, East					
China	[4]	[4]	-	Y	Y
Hong Kong	-	-	-		
Democratic People’s Republic of Korea (North Korea)	-	-	-		
Taiwan	-	-	-		
Asia, South					
Afghanistan	-	-	-		
Bangladesh	[8]	[9]	-	N	N
Bhutan	-	-	-		
India	[4, 10, 11]	[4]	-	Y	Y

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Nepal	-	-	-		
Pakistan	-	[12]	-	N	Y
Asia, Southeast					
Cambodia	-	-	-		
Indonesia	-	-	-		
Lao People’s Democratic Republic	-	-	-		
Malaysia	-	-	-		
Maldives	-	-	-		
Mauritius	-	-	-		
Mayotte	-	-	-		
Myanmar	-	-	-		
Philippines	-	-	-		
Reunion Island	-	-	-		
Seychelles	-	-	-		
Sri Lanka	-	-	-		
Thailand	[13]	-	-	Y	Y
Timore Leste	-	-	-		
Viet Nam	-	-	-		
Australasia					
Australia	[14, 15]	-	-	Y	Y
New Zealand	[4]	[3, 4]	-	Y	Y
Caribbean					
Anguilla	-	-	-		
Antigua and Barbuda	-	-	-		
Aruba	-	-	-		
Bahamas	-	-	-		
Barbados	-	-	-		
Belize	-	-	-		
Bermuda	-	-	-		
British Virgin Islands	-	-	-		
Cayman Islands	-	-	-		
Cuba	-	-	-		
Dominica	-	-	-		
Dominican Republic	-	-	-		
French Guiana	-	-	-		
Grenada	-	-	-		
Guadaloupe	-	-	-		
Guyana	-	-	-		
Haiti	-	-	-		

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Jamaica	-	-	-		
Martinique	-	-	-		
Montserrat	-ersus	-	-		
Netherlands Antilles	-	-	-		
Puerto Rico	-	[16]	-	N	N
Saint Kitts and Nevis	-	-	-		
St. Lucia	-	-	-		
St. Vincent	-	-	-		
Suriname	-	-	-		
Trinidad and Tobago	-	-	-		
Turks and Caicos Islands	-	-	-		
Europe, Central					
Albania	-	-	-		
Bosnia and Herzegovina	-	-	-		
Bulgaria	[4]	[4]	-	Y	Y
Croatia	-	-	-		
Czech Republic	-	-	-		
Hungary	[17]	-	-	N	N
Kosovo	-	-	-		
Poland	-	-	-		
Romania	[4]	[4]	-	Y	Y
Serbia and Montenegro	-	-	-		
Slovakia	-	-	-		
Slovenia	-	-	-		
The Former Yugoslav Republic of Macedonia	-	-	-		
Yugoslavia	-	-	-		
Europe, Eastern					
Belarus	-	-	-		
Estonia	-	-	-		
Latvia	-	-	-		
Lithuania	-	-	-		
Republic of Moldova	-	-	-		
Russian Federation	-	-	-		
Ukraine	[4, 18]	[4, 18]	[4, 18]	Y	Y
Europe, Western					
Andorra	-	-	-		
Austria	-	-	-		
Belgium	[4]	[4]	-	Y	Y
Channel Islands	-	-	-		

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Cyprus	-	-	-		
Denmark	-	-	-		
Faeroe Islands	-	-	-		
Finland	[19, 20]	[21]	-	Y	Y
France	[4, 22, 23]	[4]	-	Y	Y
Germany	[4, 24-27]	[4, 24, 25]	-	Y	Y
Gibraltar	-	-	-		
Greece	-	-	-		
Greenland	-	-	-		
Holy See	-	-	-		
Iceland	-	-	-		
Ireland	[28]	-	-	N	N
Isle of Man	-	-	-		
Israel	[4]	[4]	-	Y	Y
Italy	[4, 29-31]	[4, 30]	[29, 30]	Y	Y
Liechtenstein	-	-	-		
Luxembourg	-	-	-		
Malta	-	-	-		
Monaco	-	-	-		
Netherlands	[4, 25, 26, 32, 33]	[4, 25, 33, 34]	[33, 35, 36]	Y	Y
Norway	[37]	-	-	Y	Y
Portugal	-	-	-		
Saint Pierre et Miquelon	-	-	-		
San Marino	-	-	-		
Spain	[4]	[4]	-	Y	Y
Sweden	-	-	-		
Switzerland	-	-	-		
United Kingdom	[31, 38, 39]	-	-	Y	Y
Latin America, Andean					
Bolivia	-	-	-		
Ecuador	-	-	-		
Peru	-	-	-		
Latin America, Central					
Colombia	[4, 40]	[4, 40]	[40]	Y	Y
Costa Rica	-	-	-		
El Salvador	-	-	-		
Guatemala	-	-	-		
Honduras	-	-	-		
Mexico	[4, 25, 26]	[4, 25, 41]	-	Y	Y

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Nicaragua	-	-	-		
Panama	-	-	-		
Venezuela	-	-	-		
Latin America, Southern					
Argentina	-	-	-		
Chile	-	[42]	[43]	Y	Y
Falkland Islands (Malvinas)	-	-	-		
Uruguay	-	-	-		
Latin America, Tropical					
Brazil	[4, 25, 26, 44, 45]	[4, 25, 45]	[45, 46]	Y	Y
Paraguay	-	-	-		
North Africa/Middle East					
Algeria	-	-	-		
Bahrain	-	-	-		
Egypt	-	-	-		
Iran (Islamic Republic of)	-	-	-		
Iraq	[4]	[4]	-	Y	Y
Jordan					
Kuwait					
Lebanon	[4]	[4, 47]		Y	Y
Libyan Arab Jamahiriya	-	-	-		
Morocco	-	-	-		
Occupied Palestinian Territory	-	-	-		
Oman	-	-	-		
Qatar	-	-	-		
Saudi Arabia	-	-	-		
Syrian Arab Republic	-	-	-		
Tunisia	-	-	-		
Turkey	[25, 26]	[25]	-	N	N
United Arab Emirates	-	-	[48]	N	Y
Western Sahara	-	-	-		
Yemen	-	-	-		
North America, High Income					
Canada	[25, 26]	[25, 49]	[49]	Y	N
United States of America	[4, 25, 26, 50]	[4, 25, 51]	[52]	Y	Y
Oceania					
American Samoa	-	-	-		
Cook Islands	-	-	-		
Fiji	-	-	-		

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
French Polynesia	-	-	-		
Guam	-	-	-		
Kiribati	-	-	-		
Marshall Islands	-	-	-		
Micronesia (Federated States of)	-	-	-		
Nauru	-	-	-		
New Caledonia	-	-	-		
Niue	-	-	-		
Northern Mariana Islands	-	-	-		
Palau	-	-	-		
Papua New Guinea	-	-	-		
Pitcairn	-	-	-		
Samoa	-	-	-		
Solomon Islands	-	-	-		
Tokelau	-	-	-		
Tonga	-	-	-		
Tuvalu	-	-	-		
Vanuatu	-	-	-		
Wallis and Futuna Islands	-	-	-		
Sub-Saharan Africa, Central					
Angola	-	-	-		
Central African Republic	-	-	-		
Congo	-	-	-		
Congo (Democratic Republic of)	-	-	-		
Equatorial Guinea	-	-	-		
Gabon	-	-	-		
Sub-Saharan Africa, East					
Burundi	-	-	-		
Comoros	-	-	-		
Djibouti	-	-	-		
Eritrea	-	-	-		
Ethiopia	[53, 54]	-	[53]	N	Y
Kenya	-	-	-		
Madagascar	-	-	-		
Malawi	-	-	-		
Mozambique	-	-	-		
Rwanda	-	-	-		
Somalia	-	-	-		
Sudan	-	-	-		

Region /Country	Anxiety – Past month prevalence (PMP)	Anxiety – Past year prevalence (PYP)	Anxiety – Lifetime prevalence (LP)	Age-specific estimates	Sex-specific estimates
Tanzania (United Republic of)	-	-	-		
Uganda	-	-	-		
Zambia	-	-	-		
Sub-Saharan Africa, Southern					
Botswana	-	-	-		
Lesotho	-	-	-		
Namibia	-	-	-		
South Africa	[4]	[4]	-	Y	Y
Swaziland	-	-	-		
Zimbabwe	[55]	-	-	N	N
Sub-Saharan Africa, West					
Benin	-	-	-		
Burkina Faso	-	-	-		
Cameroon	-	-	-		
Cape Verde	-	-	-		
Chad	-	-	-		
Cote d'Ivoire	-	-	-		
Gambia	-	-	-		
Ghana	-	-	-		
Guinea	-	-	-		
Guinea-Bissau	-	-	-		
Liberia	-	-	-		
Mali	-	-	-		
Mauritania	-	-	-		
Niger	-	-	-		
Nigeria	[4]	[4, 56, 57]	[56]	Y	Y
Saint Helena	-	-	-		
Sao Tome and Principe	-	-	-		
Senegal	-	-	-		
Sierra Leone	-	-	-		
Togo	-	-	-		

3.2 Remission data

Data pertaining to remission of anxiety disorders were derived from general population cohort studies, and naturalistic longitudinal studies of outpatient samples or samples identified through case registers. Remission was defined as no longer meeting diagnostic criteria for the anxiety disorder. Studies that reported a follow-up of less than two years were excluded, as were those reporting on the same cohort.

Work is continuing on sourcing and extracting data for remission of anxiety disorders. Preliminary estimates and calculations will be available in January 2009.

3.3 Mortality data

Estimates of excess mortality are sought for each disorder. Where a high quality meta-analysis of excess mortality has been carried out, the derived mortality measurement will be used, with clear documentation of the source of data and authors of the study.

The data is currently being collated and estimates will be available in January 2009.

4.0 Principles for data manipulation and imputation

4.1 Prevalence estimates - data manipulation and imputation

Missing past month prevalence estimates

Many studies report the 'lifetime' risk of mental disorders but not past month prevalence. A decision was made to apply the observed proportions, derived from studies that reported prevalence of lifetime, 12-month and past month mental disorders, to countries that only reported lifetime or 12-month cases. Where possible, and based upon studies rated as being of sufficiently high quality, region-specific proportions of past year cases among lifetime cases were applied (population-weighted if estimates were available from more than one country).

Prevalence estimates for anxiety disorder 'health states'

For the purposes of GBD anxiety disorders will be disaggregated into proportions of mild, moderate and severe anxiety disorder cases. For consistency, a decision was made to use the WMHS CIDI Severity Measure to calculate proportions for the health state categories for each region for which that data is available. Therefore the WMHS data will be used to calculate proportions of mild, moderate and severe cases of anxiety disorders at a population level. These proportions can then be applied to overall estimates of prevalence for each region to derive region-specific prevalence of mild, moderate and severe anxiety disorders.

Missing age-specific estimates

Many studies only report an estimate for one overall age range, whereas the GBD study requires more age-specific estimates. A decision was made to apply the observed age pattern from countries that reported age-specific prevalence to countries where that data is not available. Where possible, and based upon studies rated as being of sufficiently high quality, region-specific rate ratios will be applied.

Missing sex-specific estimates

Some studies do not report a male/female specific estimate. A decision was made to apply the observed sex ratios from countries that reported male and female estimates to countries that reported only an overall prevalence estimate. Where possible and based on studies rated as being of sufficiently high quality, region-specific sex ratios will be applied (population-weighted if estimates were available from more than one country).

No direct country-specific estimates of prevalence of any sort

Further attempts will be made to source prevalence data for countries for which no data has yet been found through searching all available sources (grey literature, contacting experts, national and NGO websites). Where no direct estimates of any sort are available, the weighted region-specific estimate, derived from studies in other countries within the region, will be applied (population-weighted if estimates were available from more than one country). In the case of depression and anxiety (which includes PTSD) countries with comparable characteristics (e.g. engaged in conflict, suffering recent natural disasters) within the same region or nearby regions will be used as the basis for a derived estimate.

No direct region-specific estimates of prevalence of any sort

Further attempts will be made to source any prevalence data for that region through all available routes (grey literature, contacting experts, national and NGO websites). Where no direct estimates of any sort are available, the region will be matched to other regions (based on population characteristics identified through sensitivity analysis), and the weighted region-specific estimate will be applied (population-weighted if estimates were available from more than one country).

Data for 1990 or 2005 are not available.

If no direct estimates are available for 1990 or 2005, but data is available for other years, attempts will be made to estimate any trend across time. If only one estimate is available and no direct estimates of trend could be made, data on trends from other countries within the same region will be used.

Multiple data sources are available for the same country and time period.

Where multiple studies have been reported for the same country in the same time period, those of low quality or not considered representative will be excluded after careful consideration, and the estimates from the remaining countries will be pooled and the median value calculated. Statistical advice will be sought on the calculation of confidence intervals around the derived median value.

Implausible estimates

Where estimates reported are thought to be implausible, based on expert opinion, possibly due to cultural differences within the survey instrument, case ascertainment or sample selection,

researchers will use indirect sources to compile estimates of what the prevalence might look like if imputations are required. This can then be used as a baseline comparison for the reported estimates.

4.2 First steps of data manipulation and imputation

The first steps of data manipulation, using decision rules agreed upon by the Expert group, have begun. Each study reporting prevalence for all anxiety disorders combined, was reviewed to determine whether multiple prevalence types (LP, PYP, PMP) were reported. Where a study was identified as reporting a past month **and** past year/lifetime prevalence estimate, all prevalence estimates reported in that study were collected. These estimates, which were assumed to have been calculated from the same sample using the same methodology, were used to calculate a ratio relative to the past month prevalence.

Table 2 presents the ratios calculated for lifetime to past year to past month prevalence. Where data was collected AND REPORTED as part of a large international collaborative study, these ratios are reported together for the easier comparison (for example the WMHS and ICPE study). The mean and median of the observed ratios are presented at the end of each list.

Further investigations will be carried out to determine if region-specific ratios can be calculated. The median of these ratios will be used to impute data from surveys that only report on past year or lifetime prevalence of anxiety disorders. Median rather than mean will be used to minimise the influence of extreme ratios. Sex specific ratios will be used for studies that report prevalence of anxiety disorders disaggregated by sex.

Table 2. Ratios of lifetime, past year and past month prevalence of anxiety disorders.

VARIOUS STUDIES	LP:PYP:PMP		
	Females	Males	Total
The National Study of Mental Health in Colombia (Postado-Villa, 2006) [40]	3.52 : 2.21 : 1	4.32 : 2.46 : 1	3.78 : 2.29 : 1
Community survey in Jesi, Italy (Gigantasco, 2006) [30]	3.47 : 1.49 : 1	2.0 : 1.0 : 1	2.66 : 1.37 : 1
World Mental Health Survey in Ukraine (Bromet, 2005) [18]	2.72 : 1.72 : 1	2.5 : 1.44 : 1	2.65 : 1.65 : 1
Florance, Italy (Faravelli, 1989) [29]			2.0 : 1
Netherlands Mental Health Survey & Incidence Study (NEMESIS) (Bijl, 1998) [33]	1.94 : 1.29 : 1	2.12 : 1.28 : 1	1.99 : 1.28 : 1
Rural community survey in Gurage, Ethiopia (Awas, 1999) [53]	1.91 : 1	2.0 : 1	1.97 : 1
The German National Health Interview and Examination Survey (GHS) [24]	: 1.56 : 1	: 1.74 : 1	: 1.61 : 1
Mean	2.71 : 1.65 : 1	2.59 : 1.58 : 1	2.51 : 1.64 : 1
Median	2.72 : 1.56 : 1	2.0 : 1.0 : 1	2.0 : 1.61 : 1

World Mental Health Survey (WHMS)	PYP : PMP	PYP : PMP	PYP : PMP
WMHS in Israel (WHO, 2008) [4]	2.94 : 1	3.00 : 1	3.00 : 1
WMHS in India (WHO, 2008) [4]	2.47 : 1	3.05 : 1	2.65 : 1
WMHS in South Africa (WHO, 2008) [4]	2.23 : 1	2.41 : 1	2.28 : 1
WMHS in Nigeria (WHO, 2008) [4]	1.93 : 1	2.16 : 1	2.00 : 1
WMHS in China (Shenzen) (WHO, 2008) [4]	2.57 : 1	2.33 : 1	1.86 : 1
WMHS in China (Beijing/Shanghai) (WHO, 2008) [4]	1.75 : 1	1.77 : 1	1.86 : 1
WMHS in Mexico (WHO, 2008) [4]	1.69 : 1	2.47 : 1	1.85 : 1
WMHS in Colombia (WHO, 2008) [4]	1.66 : 1	1.71 : 1	1.68 : 1
WMHS in USA (WHO, 2008) [4]	1.62 : 1	1.8 : 1	1.67 : 1
WMHS in New Zealand (WHO, 2008) [4]	1.59 : 1	1.77 : 1	1.65 : 1
WMHS in Ukraine (WHO, 2008) [4]	1.64 : 1	1.56 : 1	1.61 : 1
WMHS in Italy (WHO, 2008) [4]	1.51 : 1	1.8 : 1	1.57 : 1
WMHS in Belgium (WHO, 2008) [4]	1.46 : 1	1.6 : 1	1.53 : 1
WMHS in SPain (WHO, 2008) [4]	1.46 : 1	1.67 : 1	1.50 : 1
WMHS in Japan (WHO, 2008) [4]	1.77 : 1	1.43 : 1	1.40 : 1
WMHS in Lebanon (WHO, 2008) [4]	1.39 : 1	1.51 : 1	1.44 : 1
WMHS in Bulgaria (WHO, 2008) [4]	1.43 : 1	1.50 : 1	1.44 : 1
WMHS in Germany (WHO, 2008) [4]	1.35 : 1	1.58 : 1	1.43 : 1
WMHS in France (WHO, 2008) [4]	1.41 : 1	1.50 : 1	1.43 : 1
WMHS in Netherlands (WHO, 2008) [4]	1.37 : 1	1.50 : 1	1.41 : 1
WMHS in Iraq (WHO, 2008) [4]	1.26 : 1	1.69 : 1	1.39 : 1
WMHS in Brazil (WHO, 2008) [4]	1.28 : 1	1.47 : 1	1.34 : 1
WMHS in Romania (WHO, 2008) [4]	1.19 : 1	1.50 : 1	1.27 : 1
Mean	1.69 : 1	1.85 : 1	1.71 : 1
Median	1.59 : 1	1.58 : 1	1.57 : 1

International Consortium in Psychiatric Epidemiology (ICPE)	LP:PYP:PMP	LP:PYP:PMP	LP:PYP:PMP
ICPE in Germany (Andrade, 2000) [25]			: 2.63 : 1
ICPE in Canada (Andrade, 2000) [25]			: 2.0 : 1
ICPE in Mexico City (Andrade, 2000) [25]			: 1.74 : 1
ICPE in USA (Andrade, 2000) [25]			: 1.65 : 1
ICPE in Sao Paulo, Brazil (Andrade, 2002) [45]	2.0 : 1.33 : 1	2.34 : 1.14 : 1	2.08 : 1.28 : 1
ICPE in Turkey (Andrade, 2000) [25]			: 1.16 : 1
Mean	2.0 : 1.33 : 1	2.34 : 1.14 : 1	2.08 : 1.74 : 1
Median	2.0 : 1.33 : 1	2.34 : 1.14 : 1	2.08 : 1.70 : 1

4.3 Remission estimates - data manipulation and imputation

Remission rates

Where several remission data sources are available across different follow-up periods, the annualised remission rates (ARR) will be calculated and pooled as per methodology described by Mathers and colleagues [58] and Saha and colleagues[59].

ARR weighted (%)

$$d = \frac{\sum[a \cdot \{-\ln(1 - b)\}/c]}{\sum a}$$

The pooled annualised remission rate will be used across all countries. While it is acknowledged that remission may differ in countries where treated prevalence differs, insufficient data (country-specific treated prevalence and difference in remission rate by country) are available to estimate country- or region-specific remission rates.

4.4 Mortality estimates - data manipulation and imputation

Mortality rates

The derived estimate for excess mortality will be used across all countries. While it is acknowledged that mortality may differ in countries where treated prevalence differs, insufficient data (country-specific treated prevalence and country-specific excess mortality estimates) are available to estimate country- or region-specific remission rates.

Reference List

1. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al., *Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.* . JAMA, 2000. **283**(15): p. 2008-12.
2. Demyttenaere, K., Bruffaerts, R., Posada-Villa, J., Gasquet, I., Kovess, V., Lepine, J.P., et al., *Prevalence, severity and unmet need for treatment of mental disorders in the World Health Organisation World Mental Health Surveys.* JAMA, 2004. **291**(21): p. 2581-2590.
3. Wells, J.E., Oakley Browne, M.A., Scott, K.M., McGee, M.A., Baxter, J., and Kokaua, J., *Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey.* Australian and New Zealand Journal of Psychiatry, 2006. **40**(10): p. 845-854.
4. *World Mental Health Survey.* 2008, WHO.
5. Cho, M.J., Kim, J.K., Jeon, H.J., Suh, T., Chung, I.W., Hong, J.P., et al., *Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults.* Journal of Nervous and Mental Disease, 2007. **195**(3): p. 203-210.
6. Lee, C.K., Kwak, Y.S., Rhee, H., Kim, Y.S., Han, J.H., and Choi, J.O., *The nationwide epidemiological study of mental disorders in Korea.* Journal of Korean Medical Science, 1987. **2**(1): p. 19-34.
7. Lee, C.K., Kwak, Y.S., Yamamoto, J., Rhee, H., and et al., *Psychiatric epidemiology in Korea: I. Gender and age differences in Seoul.* Journal of Nervous and Mental Disease. , 1990. **178**(4): p. 242-246.
8. Islam, M.M., Ali, M., Ferroni, P., Underwood, P., and Alam, M.F., *Prevalence of psychiatric disorders in an urban community in Bangladesh.* General Hospital Psychiatry, 2003. **25**(5): p. 353-357.
9. Mullick, M.S.I. and Goodman, R., *The prevalence of psychiatric disorders among 5-10 year olds in rural, urban and slum areas in Bangladesh - An exploratory study.* Social Psychiatry and Psychiatric Epidemiology, 2005. **40**(8): p. 663-671.
10. Joshi, K., Kumar, R., and Avasthi, A., *Morbidity profile and its relationship with disability and psychological distress among elderly people in Northern India.* International Journal of Epidemiology, 2003. **32**(6): p. 978-987.
11. Pillai, A., Patel, V., Cardozo, P., Goodman, R., Weiss, H.A., and Andrew, G., *Non-traditional lifestyles and prevalence of mental disorders in adolescents in Goa, India.* The British Journal of Psychiatry, 2008. **192**: p. 45-51.
12. Niaz, U., Hassan, S., Husain, H., and Siddiqui, S.S., *A cross-sectional study of the frequency of psychiatric morbidity in affluent urban population of Karachi.* Pakistan Journal of Medical Sciences, 2004. **20**(4): p. 337-344.
13. Van Griensven, F., Chakkraband, M.L.S., Thienkrua, W., Pengjuntr, W., Lopes Cardozo, B., Tantipiwatanaskul, P., et al., *Mental health problems among adults in tsunami-affected areas in southern Thailand.* Journal of the American Medical Association, 2006. **296**(5): p. 537-548.
14. ABS, *National Survey of Mental Health and Wellbeing 1997 (SMHWP)* Australian Bureau Statistics, 1997: p. 1-11.
15. Sanderson, K. and Andrews, G., *Prevalence and severity of mental health-related disability and relationship to diagnosis.* Psychiatric Services, 2002. **53**(1): p. 80-86.
16. Canino, G., Shrout, P.E., Rubio-Stipec, M., Bird, H.R., Bravo, M., Ramirez, R., et al., *The DSM-IV Rates of Child and Adolescent Disorders in Puerto Rico: Prevalence, Correlates, Service Use, and the Effects of Impairment.* Archives of General Psychiatry, 2004. **61**(1): p. 85-93.

17. Szadoczky, E., Rozsa, S., Zambori, J., and Furedi, J., *Anxiety and mood disorders in primary care practice*. International Journal of Psychiatry in Clinical Practice, 2004. **8**(2): p. 77-84.
18. Bromet, E.J., Gluzman, S.F., Paniotto, V.I., Webb, C.P.M., Tittle, N.L., Zakhosha, V., et al., *Epidemiology of psychiatric and alcohol disorders in Ukraine: Findings from the Ukraine World Mental Health Survey*. Social Psychiatry and Psychiatric Epidemiology, 2005. **40**(9): p. 681-690.
19. Aalto-Setälä, T., Marttunen, M., Tuulio-Henriksson, A., Poikolainen, K., and Lonnqvist, J., *One-month prevalence of depression and other DSM-IV disorders among young adults*. Psychological Medicine, 2001. **31**(5): p. 791-801.
20. Almqvist, F., Puura, K., Kumpulainen, K., Tuompo-Johansson, E., Henttonen, I., Huikko, E., et al., *Psychiatric disorders in 8-9-year-old children based on a diagnostic interview with the parents*. European Child and Adolescent Psychiatry, 1999. **8**(SUPPL. 4): p. 17-28.
21. Pirkola, S., Isometsä, E., Survisaari, J., Aro, H., Joukamaa, M., Poikolainen, K., et al., *DSM-IV mood-anxiety and alcohol disorders and their comorbidity in the Finnish general population. results from the Health 2000 Study*. Social Psychiatry and Psychiatric Epidemiology 2005. **40**: p. 1-10.
22. Ritchie, K., Artero, S., Beluche, I., Ancelin, M.L., Mann, A., Dupuy, A.M., et al., *Prevalence of DSM-IV psychiatric disorder in the French elderly population*. Br J Psychiatry, 2004. **184**: p. 147-52.
23. Mathet, F., Martin-Guehl, C., Maurice-Tison, S., and Bouvard, M.P., *Prevalence of depressive disorders in children and adolescents attending primary care. A survey with the Aquitaine Sentinelle Network*. Encephale, 2003. **29**(5): p. 391-400.
24. Jacobi, F., Wittchen, H.U., Holting, C., Hofler, M., Pfister, H., Müller, N., et al., *Prevalence, co-morbidity and correlates of mental disorders in the general population: Results from the German Health Interview and Examination Survey (GHS)*. Psychological Medicine, 2004. **34**(4): p. 597-611.
25. Andrade, L., Caraveo-Anduaga, J.J., Berglund, P., Bijl, R., Kessler, R.C., Demler, O., et al., *Cross-national comparisons of the prevalences and correlates of mental disorders*. Bulletin of the World Health Organization, 2000. **78**(4): p. 413-426.
26. WHO, *Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology*. Bulletin of the World Health Organization, 2000. **78**(4): p. 413-26.
27. Meyer, C., Rumpf, H.J., Hapke, U., and John, U., *Prevalence of DSM-IV psychiatric disorders including nicotine dependence in the general population: Results from the Northern German TACOS study*. Neurology Psychiatry and Brain Research, 2001. **9**(2): p. 75-80.
28. Lynch, F., Mills, C., Daly, I., and Fitzpatrick, C., *Challenging times: Prevalence of psychiatric disorders and suicidal behaviours in Irish adolescents*. Journal of Adolescence, 2006. **29**(4): p. 555-573.
29. Faravelli, C., Guerrini Degl'Innocenti, B., and Giardinelli, L., *Epidemiology of anxiety disorders in Florence*. Acta Psychiatrica Scandinavica, 1989. **79**(4): p. 308-312.
30. Gigantesco, A., Palumbo, G., Mirabella, F., Pettinelli, M., and Morosini, P., *Prevalence of psychiatric disorders in an Italian town: Low prevalence confirmed with two different interviews*. Psychotherapy and Psychosomatics, 2006. **75**(3): p. 170-176.
31. Ford, T., Goodman, R., and Meltzer, H., *The British child and adolescent mental health survey 1999: The prevalence of DSM-IV disorders*. Journal of the American Academy of Child and Adolescent Psychiatry, 2003. **42**(10): p. 1203-1211.
32. De Graaf, R., Van Dorsselaer, S., Ten Have, M., Schoemaker, C., and Vollebergh, W.A.M., *Seasonal variations in mental disorders in the general population of a country with a maritime climate: Findings from the Netherlands mental health survey and incidence study*. American Journal of Epidemiology, 2005. **162**(7): p. 654-661.

33. Bijl, R., Ravelli, A., and van Zessen, G., *Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS)*. *Social Psychiatry and Psychiatric Epidemiology*, 1998. **33**(12): p. 587-595.
34. Bijl, R., de Graaf, R., Ravelli, A., Smit, F., and Vollebergh, W.A.M., *Gender and age-specific first incidence of DSM-3R psychiatric disorders in the general population*. *Social Psychiatry and Psychiatric Epidemiology*, 2002. **37**: p. 372-379.
35. Bremmer, M.A., Beekman, A.T.F., Deeg, D.J.H., Van Balkom, A.J.L.M., Van Dyck, R., and Van Tilburg, W., *Anxiety disorders in later life: A study of prevalence and risk factors*. *Tijdschrift voor Psychiatrie*, 1997. **39**(8): p. 634-648.
36. Verhulst, F.C., Van der Ende, J., Ferdinand, R.F., and Kasius, M.C., *The prevalence of DSM-III-R diagnoses in a national sample of dutch adolescents*. *Archives of General Psychiatry*, 1997. **54**(4): p. 329-336.
37. Sandanger, I., Nygard, J.F., Ingebrigtsen, G., Sorensen, T., and Dalgard, O.S., *Prevalence, incidence and age at onset of psychiatric disorders in Norway*. *Social Psychiatry and Psychiatric Epidemiology*, 1999. **34**(11): p. 570-579.
38. Green, H., McGinnty, A., Meltzer, H., Ford, T., and Goodman, R., *Mental Health of Children and Young People in Great Britain, 2004*. UK National Statistics, 2004: p. 1-156.
39. McConnell, P., Bebbington, P., McClelland, R., Gillespie, K., and Houghton, S., *Prevalence of psychiatric disorder and the need for psychiatric care in northern Ireland: Population study in the district of Derry*. *SO: Source British Journal of Psychiatry*. Vol 181(3), Sep 2002, pp. 214-219, 2002. **181**(3): p. 214-219.
40. Posada-Villa, J., Buitrago-Bonilla, J.P., Medina-Barreto, Y., and Rodríguez-Ospina, M., *Trastornos de ansiedad según distribución por edad, género, variaciones por regiones, edad de aparición, uso de servicios, estado civil y funcionamiento/discapacidad según el Estudio Nacional de Salud Mental-Colombia*. Nova - Publicacion Cientifica, 2006: p. 33-41.
41. Medina-Mora, M.E., Borges, G., Lara, C., Benjet, C., Blanco, J., Fleiz, C., et al., *Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in Mexico: Results from the Mexican National Comorbidity Survey*. *Psychological Medicine*, 2005. **35**(12): p. 1773-1783.
42. Vicente, B., Kohn, R., Rioseco, P., Saldivia, S., Levav, I., and Torres, S., *Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study*. *American Journal of Psychiatry*, 2006. **163**(8): p. 1362-1370.
43. Vicente, B., Rioseco, P., Saldivia, S., Kohn, R., and Torres, S., *[Chilean study on the prevalence of psychiatric disorders (DSM-III-R/CIDI) (ECP)]*. *Revista medica de Chile*, 2002. **130**(5): p. 527-36.
44. Fleitlich-Bilyk, B. and Goodman, R., *Prevalence of child and adolescent psychiatric disorders in Southeast Brazil*. *Journal of the American Academy of Child and Adolescent Psychiatry*, 2004. **43**(6): p. 727-734.
45. Andrade, L., Walters, E.E., Gentil, V., and Laurenti, R., *Prevalence of ICD-10 mental disorders in a catchment area in the city of Sao Paulo, Brazil*. *Social Psychiatry and Psychiatric Epidemiology*, 2002. **37**(7): p. 316-325.
46. Almeida-Filho, N., De Jesus Mari, J., Coutinho, E., Franca, J.F., Fernandes, J., Andreoli, S.B., et al., *Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates*. *British Journal of Psychiatry*, 1997. **171**(DEC.): p. 524-529.
47. Karam, E.G., Mneimneh, Z.N., Karam, A.N., Fayyad, J.A., Nasser, S.C., Chatterji, S., et al., *Prevalence and treatment of mental disorders in Lebanon: A national epidemiological survey*. *Lancet*, 2006. **367**(9515): p. 1000-1006.
48. Abou-Saleh, M.T., Ghubash, R., and Daradkeh, T.K., *Al ain community psychiatric survey. I. Prevalence and socio-demographic correlates*. *Social Psychiatry and Psychiatric Epidemiology*, 2001. **36**(1): p. 20-28.

49. Nguyen, C.T., Fournier, L., Bergeron, L., Roberge, P., and Barrette, G.v., *Correlates of depressive and anxiety disorders among young Canadians*. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005. **50**(10): p. 620-8.
50. Ostir, G.V. and Goodwin, J.S., *Anxiety in persons 75 and older: Findings from a tri-ethnic population*. Ethnicity and Disease, 2006. **16**(1): p. 22-27.
51. Narrow, W.E., Rae, D.S., Robins, L.N., and Regier, D.A., *Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates*. Archives of General Psychiatry, 2002. **59**(2): p. 115-123.
52. Angold, A., Erkanli, A., Farmer, E.M.Z., Fairbank, J.A., Burns, B.J., Keeler, G., et al., *Psychiatric disorder, impairment, and service use in rural African American and white youth*. Archives of General Psychiatry, 2002. **59**(10): p. 893-901.
53. Awas, M., Kebede, D., and Alem, A., *Major mental disorders in Butajira, southern Ethiopia*. Acta Psychiatrica Scandinavica, Supplement, 1999. **99**(397): p. 56-64.
54. Fekadu, D., Alem, A., and Hagglof, B., *The prevalence of mental health problems in Ethiopian child laborers*. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2006. **47**(9): p. 954-959.
55. Abas, M.A. and Broadhead, J.C., *Depression and anxiety among women in an urban setting in Zimbabwe*. Psychological Medicine, 1997. **27**(1): p. 59-71.
56. Gureje, O., Lasebikan, V.O., Kola, L., and Makanjuola, V.A., *Lifetime and 12-month prevalence of mental disorders in the Nigerian Survey of Mental Health and Well-Being*. British Journal of Psychiatry, 2006. **188**(MAY): p. 465-471.
57. Adewuya, A.O., Ola, B.A., and Adewumi, T.A., *The 12-month prevalence of DSM-IV anxiety disorders among Nigerian secondary school adolescents aged 13-18 years*. Journal of adolescence, 2007 Dec, 30(6):1071-6. Epub: 2007 Sep 17, 2007.
58. Mathers, C.D., Vos, T., Lopez, A.D., Solomon, J., and Ezzati, M., eds. *National burden of disease studies: a practical guide. Global program on evidence for health policy*. 2001, World Health Organisation: Geneva.
59. Saha, S., Barendregt, J.J., Vos, T., Whiteford, H., and McGrath, J., *Modelling disease frequency measures in schizophrenia epidemiology*. Schizophrenia Research, 2008. **104**(1-3): p. 246-254.

Appendix

Flowchart of systematic data search for Mental Disorders

